High Potency API Contract Manufacturing Market Report 2022: Featuring Piramal Pharma Solutions, Lonza, Pfizer, Catalent & More - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report by Product Type (Innovative, Generic), by Dosage Form (Injectable, Creams), by Application, by Synthesis, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global high potency API contract manufacturing market size is expected to reach USD 14.65 billion by 2030, registering a CAGR of 9.0% over the forecast period, according to this report. The main drivers of this market are rising demand for oncology drugs, advancements in manufacturing technology, and a rise in capacity to meet the increasing demand. Also, a rise in target therapies to cure chronic diseases is going to accelerate industry growth. The COVID-19 pandemic boosted the demand for high potency APIs (HPAPIs). During the first half of the pandemic, the supply chain was disrupted, which reduced research-based activities.

However, during the second half, the industry started to gain importance due to a rise in demand for vaccines to fight the coronavirus. This rise has also increased the demand for raw materials and product intermediates of API molecules. Moreover, the growing demand for HPAPI molecules during the COVID-19 pandemic has led to the price hike of the same, thus boosting revenue growth in 2020 and 2021. There has been a rise in the outsourcing activities of high potency active pharmaceuticals as it removes the need for investment in expensive infrastructure for containing it.

Also, the installation & maintenance of the facility is complex and requires specialized engineers. The high cost of producing high potency API in-house, combined with the pressure to produce affordable drugs, has significantly contributed to the increasing outsourcing activities by companies. A wide range of outsourcing providers offers HPAPI services, thus making it difficult for companies to choose an appropriate CDMO. The large-scale CDMOs become the most likely choice as they provide large volumes. However, due to the small volumes required for dosage, small-scale providers are also gaining importance.

High Potency API Contract Manufacturing Market Report Highlights

• The product type segment is classified into innovative and generic. The innovative segment accounted for the largest revenue share in 2021
• Based on applications, the oncology segment dominated the industry in 2021 due to a rise in research on new cancer drugs and therapies
• The oral solids dosage form segment is anticipated to witness the fastest growth rate during the forecast period
• By synthesis, the industry is classified into synthetic and biotech. The biotech segment is estimated to witness a significant growth rate from 2022 to 2030
• The Asia Pacific region is estimated to register the fastest CAGR during the forecast period due to the presence of the largest manufacturers of APIs across the globe, such as China

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. High Potency API (HPAPI) Contract Manufacturing Market Variables, Trends & Scope

Chapter 4. High Potency API (HPAPI) Contract Manufacturing Market: Product Type Segment Analysis

Chapter 5. High Potency API (HPAPI) Contract Manufacturing Market: Application Segment Analysis

Chapter 6. High Potency API (HPAPI) Contract Manufacturing Market: Synthesis Segment Analysis

Chapter 7. High Potency API (HPAPI) Contract Manufacturing Market: Dosage Form Segment Analysis

Chapter 8. High Potency API (HPAPI) Contract Manufacturing Market: Regional Analysis

Chapter 9. Competitive Landscape

Companies Mentioned

• Piramal Pharma Solutions
• Lonza
• Catalent Inc
• VxP Pharma, Inc.
• Pfizer CentreOne
• Gentec Pharmaceutical Group
• AbbVie
• Aurigene Pharmaceutical Services Ltd.
• CordenPharma International
• Curia Global, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/o0jcu6

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900